S 2126

Regenerative Medicine Promotion Act of 2014

Congress: 113 (2013–2015, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Mar 13, 2014
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 13, 2014)
Official Text: https://www.congress.gov/bill/113th-congress/senate-bill/2126

Sponsor

Name: Sen. Boxer, Barbara [D-CA]
Party: Democratic • **State:** CA • **Chamber:** Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Kirk, Mark Steven [R-IL]	R · IL		Mar 13, 2014
Sen. Baldwin, Tammy [D-WI]	D · WI		Apr 30, 2014
Sen. Landrieu, Mary L. [D-LA]	D · LA		Apr 30, 2014
Sen. Booker, Cory A. [D-NJ]	D · NJ		May 20, 2014
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Jun 23, 2014

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 13, 2014

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Mar 13, 2014)

Regenerative Medicine Promotion Act of 2014 - Requires the Comptroller General to submit to Congress a report identifying all ongoing federal programs and activities regarding regenerative medicine.

Directs the Secretary of Health and Human Services (HHS) to establish a Regenerative Medicine Coordinating Council, which shall:

- prepare a national strategy to support research into regenerative medicine and enable the development of drugs, biological products, medical devices, and biomaterials for use in regenerative medicine;
- develop national goals for regenerative medicine research and product development;
- prepare a plan specifying priorities for research into regenerative medicine;
- identify sources of funding for research into regenerative medicine and areas where such funding is inadequate or duplicative;
- make recommendations regarding federal policies to support development and marketing of regenerative medicine products;
- develop consensus standards regarding scientific issues critical to regulator approval of regenerative medicine products; and
- determine the need for establishing centers of excellence or consortia to further advance regenerative medicine.

Directs the Council to: (1) adopt procedures to ensure the receipt of public input; and (2) submit an annual report on its activities to Congress, the Director of the National Institutes of Health (NIH), and the Commissioner of Food and Drugs (FDA).

Actions Timeline

- **Mar 13, 2014:** Introduced in Senate
- **Mar 13, 2014:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.